Hepatitis B Treatment Market Trends

Growth Drivers

• Novel Approach of Drug Manufacturers for the Development of Therapeutic Drugs for the Cure of Hepatitis B Virus to Drive the Market Growth - The spread of communicable diseases is a major concern amongst nations worldwide. To fight the spread of such diseases, the United Nations has outlined the 2030 Agenda for Sustainable Development, which further lays down 17 sustainable development goals, focused on different challenging aspects. Viral hepatitis, which is an international public health challenge, has raised the focus of government bodies, such as the World Health Organization (WHO), for formulating strategies that can help to achieve the laid down targets for 2030. As such, the WHO has defined a set of five strategic decisions to promote drug manufacturers globally and to support countries in spreading the awareness of communicable disease.
  
  Backed by the increasing support of the governmental bodies, as well as the support of the government of nations across the world, the drug manufacturers in the pharmaceutical industry are significantly expanding their focus on the research and development of new drugs that can help to cure hepatitis B, which is anticipated to drive the market growth. Additionally, significant spending by the government of nations to promote research and the rising awareness amongst the individuals for the early detection of the viral infection are some of the additional factors anticipated to drive the growth of the hepatitis B treatment market during the forecast period.

Challenges

• Lack of Proper Healthcare Infrastructure in Several Nations to Hamper the Market Growth - Although there is a significant amount of research and development happening in the field of developing novel drugs and therapies for the cure of hepatitis B, yet the unavailability of a proper healthcare infrastructure in several nations where the prevalence of the viral infection is significantly high, is one of the major factors anticipated to hamper the market growth. Moreover, the long-standing process for the approval of a novel drug, and the high cost of treatment in several developing nations are some of the additional factors anticipated to lower the growth of the global hepatitis B treatment market in the coming years.